2021
DOI: 10.3389/fphar.2020.618238
|View full text |Cite
|
Sign up to set email alerts
|

Guidance for Demonstrating the Societal Value of new Antibiotics

Abstract: Given that antibiotic use is associated with externalities, standard economic evaluation which considers costs and health gains accruing to patients under-values antibiotics. Informed by a scoping review, this discussion paper aims to identify the societal value elements of antibiotics and to provide guidance on how these value elements can be incorporated in economic evaluation. With a view to appropriately quantify the societal value of antibiotics, there is a need for good practice guidelines on the methodo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 20 publications
0
10
0
Order By: Relevance
“…Although accounting for the characteristics of advanced therapies runs the risk that these products are treated in a different way from a health economic perspective than other medicines, there have been numerous calls from various stakeholders in multiple countries to apply specific considerations to the reimbursement and market access of advanced therapies ( van Overbeeke et al, 2021 ). This is similar to the way that other types of innovative medicines such as (ultra-)orphan drugs ( Nestler-Parr et al, 2018 ), antibiotics ( Simoens and Spriet, 2020 ), or vaccines ( Annemans et al, 2021 ) may receive special attention in value assessment and reimbursement.…”
Section: Introductionmentioning
confidence: 74%
“…Although accounting for the characteristics of advanced therapies runs the risk that these products are treated in a different way from a health economic perspective than other medicines, there have been numerous calls from various stakeholders in multiple countries to apply specific considerations to the reimbursement and market access of advanced therapies ( van Overbeeke et al, 2021 ). This is similar to the way that other types of innovative medicines such as (ultra-)orphan drugs ( Nestler-Parr et al, 2018 ), antibiotics ( Simoens and Spriet, 2020 ), or vaccines ( Annemans et al, 2021 ) may receive special attention in value assessment and reimbursement.…”
Section: Introductionmentioning
confidence: 74%
“…There are no established methods for assessing broader value, despite numerous recommendations to consider them for novel antimicrobials and vaccines (3,(10)(11)(12). Key elements of this broader value include insurance value and enablement value (3,6,10,14).…”
Section: Gaps In Approaches For Assessing Valuementioning
confidence: 99%
“…Thirdly, there is increasing appetite for Outcomes Based Agreements to better align commercial arrangements around patient value. Finally, broader frameworks for valuing novel antimicrobials and vaccines (3,5,6,(10)(11)(12) have also been recommended internationally.…”
mentioning
confidence: 99%
“…For educational purposes, the same group of stakeholders need to address customized aspects of political, socio-economic, commercial and cultural ethics if the different stakeholders in antibiotic overuse are to be persuaded to change their current practices [ 45 , 47 ]. In this way, ethical considerations should be balanced between the conservation of existing antibiotics, the acceleration of new antibiotic development, potential regulatory hurdles and the conservation of antibiotic safety and efficacy [ 48 , 49 ].…”
Section: Ethical Perspectives On the Overuse Use Of Antibioticsmentioning
confidence: 99%